A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic underpinnings of weight loss response has identified a gene, neurobeachin (NBEA), as a predictor of how individuals ...
Jul 21, 2025
0
30
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and liraglutide. These results ...
Jul 9, 2025
0
35
Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment options, some migraine ...
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.
Jun 20, 2025
0
29
People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented ...
Jun 17, 2025
0
13
Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at the European Congress on ...
May 13, 2025
0
13
Medications like semaglutide and liraglutide may help to reduce the risk of heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and diabetes following bariatric ...
May 13, 2025
0
16
Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research presented at the European Congress on Obesity (ECO 2025) has found.
May 9, 2025
0
75
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy ...
Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends, according to a study published online Jan. 29 in JAMA Network Open.
Feb 6, 2025
0
36
